Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04439006 · ClinicalTrials.gov registry record · Phase 1
Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization
A Phase 1 study of Malignant Solid Neoplasm and Myelodysplastic Syndrome, sponsored by Jennifer Woyach.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT04439006: Completed Phase 1 study of Malignant Solid Neoplasm and Myelodysplastic Syndrome, sponsored by Jennifer Woyach.
NCT04439006 is a Phase 1 study of Malignant Solid Neoplasm and Myelodysplastic Syndrome that has completed, run by Jennifer Woyach. The registered enrollment target is 10 participants, below the 1,141-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04439006, a Phase 1 study of Malignant Solid Neoplasm and Myelodysplastic Syndrome, has completed, sponsored by Jennifer Woyach.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase Ib/II trial studies the side effects and best dose of ibrutinib and how well it works in treating patients with COVID-19 requiring hospitalization. Ibrutinib may help improve COVID-19 symptoms by lessening the inflammatory response in the lungs, while preserving overall immune function. This may reduce the need to be on a ventilator to help with breathing.
Primary Outcome
Associations between baseline characteristics and the primary endpoint will be evaluated with logistic regression, adjusting for arm. These analyses will be largely descriptive, as a result of a limited sample size.
Conditions Studied
Interventions
- OTHER Best Practice
- DRUG Ibrutinib
Study Locations (1)
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2020-10-23 |
| Est. Completion | 2022-09-20 |
| Phase | Phase 1 |
What the finished NCT04439006 record still lists
NCT04439006 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 1,141-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (99% lower).
The record links to 7 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Best Practice is the first listed.
NCT04439006 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT04439006 about?
NCT04439006 is a clinical study titled "Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization". This phase Ib/II trial studies the side effects and best dose of ibrutinib and how well it works in treating patients with COVID-19 requiring hospitalization. Ibrutinib may help improve COVID-19 symptoms by lessening the inflammatory response in the lungs, while preserving overall immune function. T...
What is the current status of trial NCT04439006?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2020-10-23. Estimated completion is 2022-09-20.
What conditions does trial NCT04439006 study?
This clinical trial studies the following conditions: Malignant Solid Neoplasm, Myelodysplastic Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, Aplastic Anemia, Monoclonal Gammopathy of Undetermined Significance.
What interventions are being tested in trial NCT04439006?
The interventions under investigation include: Best Practice (OTHER), Ibrutinib (DRUG).
Who is sponsoring clinical trial NCT04439006?
This trial is sponsored by Jennifer Woyach, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04439006 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04439006's enrollment target sits among peer trials
10 170th of 176 higher than 5 of 176 other Malignant Solid Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Solid Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia
RECRUITING · Phase 1
-
Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients
RECRUITING · Phase 1
-
Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction
RECRUITING · Phase 1
-
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
RECRUITING · Phase 1
-
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI